TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Return
18.15%
This Quarter Return
+5.19%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.8B
AUM Growth
+$97.9M
(+3.6%)
Cap. Flow
-$25.2M
Cap. Flow
% of AUM
-0.9%
Top 10 Holdings %
Top 10 Hldgs %
45.4%
Holding
164
New
19
Increased
21
Reduced
19
Closed
12
Top Buys
| 1 |
Gilead Sciences
GILD
|
$22M |
| 2 |
Thermo Fisher Scientific
TMO
|
$15.1M |
| 3 |
Teva Pharmaceuticals
TEVA
|
$13M |
| 4 |
Johnson & Johnson
JNJ
|
$11M |
| 5 |
Edwards Lifesciences
EW
|
$10.6M |
Top Sells
| 1 |
iShares Biotechnology ETF
IBB
|
$23.6M |
| 2 |
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
|
$12.8M |
| 3 |
Biogen
BIIB
|
$12.6M |
| 4 |
Amgen
AMGN
|
$12M |
| 5 |
Puma Biotechnology
PBYI
|
$11.6M |
Sector Composition
| 1 | Healthcare | 93.03% |
| 2 | Real Estate | 2.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
151
Dynavax Technologies
DVAX
$1.17B
| – | – |
-345,050
| Closed | -$3.33M |
|
|
152
iShares Biotechnology ETF
IBB
$5.68B
| – | – |
-227,910
| Closed | -$23.6M |
|
153
Intellia Therapeutics
NTLA
$1.25B
| – | – |
-28,000
| Closed | -$448K |
|
|
SAGE
154
DELISTED
Sage Therapeutics
SAGE
| – | – |
-90,480
| Closed | -$7.21M |
|
155
Salarius Pharmaceuticals
SLRX
$2.42M
| – | – |
-2
| Closed | -$614K |
|
156
Travere Therapeutics
TVTX
$1.89B
| – | – |
-167,949
| Closed | -$3.26M |
|
|
MDRX
157
DELISTED
Veradigm Inc. Common Stock
MDRX
| – | – |
-47,300
| Closed | -$604K |
|
|
PRTK
158
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| – | – |
-533,000
| Closed | -$12.8M |
|
|
NBRV
159
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
| – | – |
-597
| Closed | -$1.68M |
|
|
AKRX
160
DELISTED
Akorn, Inc.
AKRX
| – | – |
-327,735
| Closed | -$11M |
|
161
Bristol-Myers Squibb
BMY
$95B
| – | – |
-186,500
| Closed | -$10.4M |
|